TY - CHAP M1 - Book, Section TI - Neuroblastoma A1 - Bagatell, Rochelle A1 - Meany, Holly A2 - Kline, Mark W. PY - 2018 T2 - Rudolph's Pediatrics, 23e AB - Neuroblastoma, a tumor of the sympathetic nervous system, is the most common extra-cranial solid tumor of childhood. Neuroblastoma is a clinically heterogeneous disease, as infants with metastatic disease may experience complete tumor regression without therapy, while other children may experience relentless disease progression despite modern multimodality therapy. Current risk classification schemes use clinical, histologic, and genomic features at diagnosis to predict tumor behavior and to assign patients to an appropriate treatment regimen based on risk of recurrence. Children with lower risk disease are spared unnecessary therapies yet still achieve excellent outcomes. Nevertheless, outcome remains poor for patients classified as high risk. Additionally, survivors of high-risk neuroblastoma are at risk for significant treatment-related adverse events, emphasizing the critical need for more effective, less toxic treatments. A better understanding of the molecular pathogenesis of neuroblastoma, including an understanding of how alterations in specific biological pathways impact tumor behavior, may lead to improved treatments. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/04/24 UR - accesspediatrics.mhmedical.com/content.aspx?aid=1182911494 ER -